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Background: Despite evidence-based recommendations supporting long-term use of cardiac medications in
patients post ST-elevation myocardial infarction, adherence is known to decline over time. Discontinuation of
cardiac medications in such patients is associated with increased mortality.
Methods/design: This is a pragmatic, cluster-randomized controlled trial with blinded outcome assessment and
embedded qualitative process evaluation. Patients from one health region in Ontario, Canada who undergo a
coronary angiogram during their admission for ST-elevation myocardial infarction and who survive their initial
hospitalization will be included. Allocation of eligible patients to intervention or usual care will take place within
one week after the angiogram using a computer-generated random sequence. To avoid treatment contamination,
patients treated by the same family physician will be allocated to the same study arm. The intervention consists of
recurrent, personalized, paper-based educational messages and reminders sent via post on behalf of the
interventional cardiologist to the patient, family physician, and pharmacist urging long-term adherence to
secondary prevention medications. The primary outcome is the proportion of patients who report in a phone
interview taking all relevant classes of cardiac medications at twelve months. Secondary outcomes to be measured
at three and twelve months include proportions of patients who report: actively taking each cardiac medication
class of interest (item-by-item); stopping medications due to side effects; taking one or two or three medication
classes concurrently; a perfect Morisky Medication Adherence Score for cardiac medication compliance; and having
a discussion with their family physician about long-term adherence to cardiac medications. Self-reported measures
of adherence will be validated using administrative data for prescriptions filled.
Discussion: This intervention is designed to be easily generalizable. If effective, it could be implemented broadly. If
it does not change medication utilization, the process evaluation will offer insights regarding how such an
intervention could be optimized in future.
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Cardiovascular disease burden and the role for long-term
pharmacotherapy
Worldwide, cardiovascular disease (CVD) is estimated
to be the leading cause of death and disability [1].
Approximately 50% of myocardial infarctions (MIs)
and 70% of CVD deaths occur in patients who have
already documented coronary artery disease (CAD)
[2]. Therefore, the prompt identification of modifiable
cardiovascular risk factors and initiation of proven sec-
ondary preventative medications post-MI are essential
to the prevention of subsequent cardiac events [3].
Population-level observational studies provide evidence
that the rate of cardiovascular morbidity and mortality
has been decreased through the use evidence-based
therapies [4,5].
ST-segment elevation myocardial infarction (STEMI)
is a common presentation of acute myocardial infarc-
tion (AMI) constituting approximately 30% of all cases
[6]. Post-STEMI, patients are at high risk for subse-
quent cardiac events—18% of men and 35% of women
will have a repeat MI within six years and STEMI
patients have four to six times the risk of sudden car-
diac death compared to the general population [7].
While acute treatment is crucial for STEMI patients,
relevant guidelines emphasize that the initiation and
long-term maintenance of evidence-based secondary
preventative therapies are essential for reducing the
overall burden of CVD [3,8,9].
Poor long-term adherence to cardiac medications
While there is a significant body of evidence supporting
these guidelines (Table 1), there remains a large gap be-
tween ideal and actual care with regard to the long-term
management of cardiovascular risk for these patients.Table 1 Summary of guideline recommendations for medicat
Medication Recommendation
Anti-platelets Aspirin therapy (75-162 mg/day) indefinitely po
P2Y12-receptor inhibitor (clopidogrel, prasugrel
in patients post ACS
P2Y12-receptor inhibitor continued for at least
stent placement
Statins Statin therapy indefinitely for all patients with
Angiotensin-system agent ACE inhibitor (or ARB if intolerant) post-STEMI
ventricular ejection fraction <40% and in those
ACE inhibitor (or ARB) for all patients post-STEM
Beta-blockers Beta-blockers for all patients post-STEMI
Beta-blockers continued for at least three years
*Strength of Evidence.
I: Conditions for which there is evidence and/or general agreement that a given tre
IIa: Weight of evidence/opinion is in favor of usefulness/efficacy.
A: Data derived from multiple randomized clinical trials or meta-analyses.
B: Data derived from a single randomized trial, or nonrandomized studies.Studies show that adherence to evidence-based therap-
ies begins decreasing at 30 days and falls to as low as
50% adherence at six months post-discharge [10-14].
Unfortunately, discontinuation of evidence-based ther-
apies has repeatedly been shown to be associated with
increased mortality in patients with CAD [15-18].
Medication non-adherence is increasingly recognized
as a very important issue due to its significant health con-
sequences [19,20]. Many reasons for non-adherence have
been proposed and these can generally be categorized as
provider-level (e.g., knowledge, motivation, time), patient-
level (e.g., knowledge, motivation, finances [21]), and
system-level (e.g., access to care, coordination of care).
Furthermore, both ethnicity [22,23] and socio-economic
status [24] seem to be related to quality of care for cardio-
vascular disease, even in countries with universal health-
care like Canada and the United Kingdom (UK), and
non-adherence related to such factors may not be readily
impacted with quality improvement interventions.
Fortunately, the evidence suggests that many of the key
factors contributing to cardiac medication non-adherence
may be amenable to intervention. Discontinuation of
evidence-based cardiac medicines post-STEMI is rarely
due to an active, informed choice after discussion of
risks and benefits between patient and health-care-
provider; absolute contraindications are rare and side
effects are infrequently reported by patients as the
primary reason for discontinuation (less than 4% of
patients) [25,26]. In contrast to situations where in
formed decisions are made to deviate from standard
treatment protocols, qualitative work in primary care has
found that poor adherence may be frequently due to
fragmented systems of care [27] or communication pro-
blems at the interface between secondary and primary
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lizations increase the risk for inadvertent discontinuation
of cardiac medications [29].
The provider also can have an impact; having a cardi-
ologist involved in the patient’s care may increase rates
of appropriate medication adherence [30]. However,
there is undesirable variation among prescription rates
by specialists as well. In one study of cardiologists, the
most common reason given for not prescribing secondary
prevention medications was, ‘not high-enough risk’ [25].
However, in that study, risk scores of patients not treated
for this reason were often higher than those of patients
prescribed such treatment. Meanwhile, the same study
found that approximately one-third of patients had stopped
their medication without instruction from their doctor.
This indicates a potential role for multi-pronged interven-
tions addressing both the provider and the patient.
Previous research aiming to improve adherence
Numerous systematic reviews have been published regard-
ing interventions to improve adherence to medications.
An overview of reviews found that no patient-mediated
interventions were effective across all diseases, but
found that the most promising interventions included
self-management, simplified dosing, and involvement of
pharmacists [31]. A review focusing on anti-depressants
found that patient education alone was ineffective [32],
and a review focusing on anti-epileptics found that pa-
tient education was inconsistent, while interventions
with multiple reminders featuring action planning were
more often effective [33]. Recognizing that non-adherence
tends to worsen over time, a recent Cochrane review
recommended testing a delayed intervention as opposed
to the immediate reminders used in similar previous trials
[34], as one would expect a larger effect size in a delayed
intervention.
One previous trial has shown that brief evidence sum-
maries regarding medications attached to discharge let-
ters sent to primary care providers resulted in improved
adherence [35]. Three other trials have evaluated the
role of reminder letters to the primary care provider
(with or without patient reminders) to improve adher-
ence to evidenced-based cardiovascular therapies: one in
the USA, one in the UK, and one in Canada [36-38].
The American trial focused on beta-blocker use post-MI
and found a small increase in compliance (proportion of
days covered), with a number needed to treat of 16 for
achieving high adherence, but no change in the propor-
tion who discontinued their beta-blocker. The other two
trials focused on statin use in patients with known CAD.
These trials found absolute increases in adherence of 9%
to 10% in statin use, but despite this being a potentially
important effect size on a population basis, both were
under-powered for effects this size.Objectives
The overarching goal of this project is to improve long-
term use of secondary prevention medications for
patients with CAD, and thereby reduce cardiovascular
events through the use of an easily generalizable and
sustainable intervention. The primary objective of this
study is to assess if repeated mailing of an educational
message and reminder to the family physician and the
patient will decrease the proportion of patients who
discontinue evidence-based secondary-prevention medi-
cations at twelve months post-STEMI. A secondary ob-
jective is to encourage cardiac patients and their
primary care providers to discuss the benefits of long-
term adherence to cardiac medications.Methods/design
Study design
DERLA-STEMI is a pragmatic, cluster-randomised
controlled trial, with blinded outcome-assessment, and
is registered with clinicaltrials.gov (NCT01325116). See
Study Flow Diagram (Figure 1).
Participants and Setting
In Ontario, healthcare is financed through a single-
payer (publicly administered) system. There are no co-
payments for visits to generalist or specialist physicians
or for care provided in hospitals for patients of any
age, and almost all licensed prescription medications
are covered for patients 65 and over. Patients younger
than 65 years pay for medications out-of-pocket or
through private insurance plans, or are covered by the
provincial plan if they qualify for social support.
In this study, eligible patients are adult patients
(>18 years) with a diagnosis of STEMI, who undergo
a coronary angiography procedure (with or without
angioplasty), at the Heart Investigation Unit (HIU) in
Hamilton, Ontario, and who are alive at hospital dis-
charge. In keeping with the pragmatic approach to
study design, no other exclusion criteria will be ap-
plied. The HIU is the only catheterization lab in its
region, with a catchment population of almost 1.5 mil-
lion people. More than 700 STEMI patients undergo
an angiogram there each year. Studies at the HIU have
highlighted excellent rates of prescribing of evidence-
based therapies at discharge post-STEMI, but substan-
tial reduction in use starting three months following
discharge [39,40]. While 78% of STEMI patients leave
the HIU taking a statin, an ACE-inhibitor (or ARB), a
beta-blocker, and aspirin, by 90 days the proportion
still taking all four of these medication classes falls to
63% (unpublished data from the Strategic Manage-
ment of Acute Reperfusion and Therapies in Acute
Myocadial Infarction (SMART-AMI) study).
Figure 1 Study Flow Diagram.
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The intervention was developed in concert with clinical
experts from both primary care and cardiology, as
well as experts in knowledge translation and medical
decision-making. Personalized letters sent via post to the
patient and their family physician at one, five, eight, and
eleven months after their angiogram, signed by the inter-
ventional cardiologist (see Additional file 1: Appendix A
for prototype). The letter for the family physician names
the patient and provides brief evidence in support of long-
term medication use for these patients. This was reviewed
and edited with a series of family physicians from a differ-
ent area of the province.
The patient letter provides a review of the import-
ance and role of each of the cardiac medications and
urges short- and long-term adherence (see Additional
file 1: Appendix B for prototype). The educational as-
pect is designed to address knowledge and beliefs about
medication use as a potential cause of poor adherence.
The intervention explicitly encourages discussion of
medication adherence with the family physician by ask-
ing patients to bring the letter to their family physician.
It also asks patients to deliver the final page of their
letter to their pharmacist; this page is written to the
pharmacist urging them to participate in promoting
long-term adherence. The intention is to facilitate re-
current discussions with primary care providers that
emphasize long-term adherence and to address coord-
ination of care and continuity of information as barriers
to medication persistence. This letter was developed
with iterative evaluations of understanding and accept-
ability amongst a series of cardiology patients at the
HIU. The language in the patient letter is simplified to
a grade six-level.The timing of the intervention was specifically chosen
based on the preliminary data obtained from the
SMART-AMI trial demonstrating suboptimal rates at
90 days. Furthermore, literature (referenced above)
demonstrates that adherence starts decreasing by thirty
days and continues to decrease in an almost linear fash-
ion. Finally, the common practice in Ontario is for phar-
macists to dispense medications for no more than three
months at a time (regardless of duration of the prescrip-
tion ordered by the physician). Therefore, we decided to
deliver the intervention at regular intervals (1, 5, 8, and
11 months post-STEMI) corresponding to the likely time
periods prior to patients requiring a prescription re-
newal/refill. In pilot testing the intervention with family
physicians and patients, we determined that sending the
full letter too frequently would be undesirable and that
the physicians in particular did not want to have monthly
reminders. At the same time, close examination of data
from Ontario indicated large stepwise declines in adher-
ence at 30 and 60 days post-STEMI. To address this,
patients will be provided an additional postcard type re-
minder two months post-STEMI (see Additional file 1:
Appendix C).
In summary, the unique aspects of the intervention
compared to usual care include the following: the letter
to the primary care provider is personalized and includes
a summary of the evidence in support of long-term ad-
herence and represents a recurrent form of contact be-
tween the cardiologist and the primary care provider;
the letter to the patient use clear language suitable for a
broad range of health literacy levels and was iteratively
refined with input from patients in the target population,
features content that attempts to address adherence-
related beliefs, and provides explicit, actionable instructions
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summary to be given to the outpatient pharmacist to facili-
tate coordination of renewals.Comparator/usual care
Usual care in this context may include some contact be-
tween the admitting physician (generally not the inter-
ventional cardiologist) for the STEMI patient and the
primary care provider (generally the family physician).
This is usually in the form of a standard discharge sum-
mary mailed to the family physician’s office at the end of
the hospitalization. The quality of such discharge sum-
maries varies widely even within the same institution
(and summaries frequently lack necessary information
regarding medications) [41]. In keeping with the prag-
matic nature of the trial, no attempt will be made to
standardize the usual care arm [42].
Allocation
The randomization schedule was computer-generated
by a statistician independent of the study, using a
permuted block design with randomly varying block
lengths of four, six, or eight. Eligible patients are randomly
allocated to one of the two treatment arms. Although
enrolment of more than one patient treated by a par-
ticular family physician is expected to occur infrequently,
randomization will be carried out to ensure that, once a
patient from any family physician is randomized, all future
patients seen by that family physician will automatically
be assigned to the same arm. This is necessary to avoid
contamination (with one family physician having patients
in different intervention arms). Roughly one-half of
patients will be allocated to each study arm (the actual al-
location ratio will depend on the size of the clusters).
Based on pilot data, we anticipate that approximately 10%
to 15% of patients will not have a family physician. In
keeping with the pragmatic design of the trial, a patient
without a family physician will be included (receiving only
the patient-level intervention).
Randomization is delayed by one week (after the
angiogram) to permit time to identify and exclude
patients with in-hospital death. Randomization will con-
tinue until the target sample size is achieved. The antici-
pated duration of enrolment is 15 months. The
allocation sequence will be concealed from the investiga-
tors and outcome assessors; only the study coordinator
who will be sending out the letters will have access to
the un-blinded allocation list.
Outcomes
The primary outcome is the proportion of living patients
who describe taking all cardiac medication classes of inter-
est measured at twelve months. This type of ‘all-or-none’measure has been recommended for evaluating quality
improvement interventions, especially related to medica-
tion utilization [43]. Specifically, we will assess whether
patients are taking a statin, beta-blocker, angiotensin
modifier (ACE or ARB), and aspirin at twelve months. All
STEMI patients have reasonable evidence supporting
these medications [3]; we anticipate that randomization
will balance those patients for whom evidence is less
clear or who might have contraindications to any of
these medications.
We will also assess whether patients are taking these
four medication classes plus a secondary antiplatelet
(clopidogrel, prasugrel, or ticagrelor) at three months.
Therefore, patients at three months will be dichotomized
as to whether or not they are taking all five cardiac
medication classes, and at twelve months they will be
dichotomized according to whether they are taking all
four relevant medication classes. The difference in the
number of medication classes considered at three and
twelve months relates to uncertainty in the evidence
regarding the appropriateness of a secondary antiplatelet
at this timeframe. Additional secondary outcomes in-
clude a comparison of: the proportion of patients who
report actively taking each cardiac medication class of
interest (item-by-item) at three and twelve months; the
proportion of patients who report stopping medications
due to side effects at three and twelve months; the pro-
portion taking one or two or three medication classes
concurrently at three and twelve months; and the pro-
portion of patients with a perfect Morisky Medication
Adherence Score (MMAS) for cardiac medication com-
pliance at three and twelve months. The MMAS is a
brief, standardized adherence questionnaire which excel-
lent reliability [44], and has been shown to be predictive
of cardiovascular medication adherence [45] and to be
associated with control of blood pressure and cholesterol
[44,46]. In addition, all patients will be asked at three
months and twelve months whether they had a discus-
sion with their family physician during past three
months in which the provider had encouraged long-
term cardiac medication compliance.
Data collection
Baseline patient characteristics will be obtained from
standard patient-registry information at the HIU. This
includes demographic information, comorbidities, and
the findings at the time of angiography.
Outcomes will be assessed 3 and 12 months post-
index angiogram through patient phone calls by a re-
search coordinator associated with the HIU who will be
trained expressly for this function. The research coord-
inator conducting the phone calls will not have access to
the allocation list. The calls are made on behalf of the
treating cardiologist at the HIU, and all patients will be
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family physician. The phone call follow-ups will ask
patients to list their current, daily medications (and doses)
without specific prompting in order to reduce bias.
Attempts will be made to contact patients for a maximum
of 30 days prior to being considered lost-to-follow-up.
Reasons for loss-to-follow-up will be tracked.
For a sample of patients aged 65 and older, the
Ontario Drug Benefit database will be used to examine
the accuracy of the self-reported primary outcome and
to further evaluate adherence using the medication pos-
session ratio over the preceding year, which has been
shown to be associated with both pill counts and clinical
effects [47].
Ethical considerations
Research Ethics Board (REB) approval was received at
Hamilton Health Sciences Centre and McMaster Univer-
sity (project number 11–191). Given the low risk nature
of the intervention, which falls within the realm of
continuity-of-care and circle-of-care, the REB agreed
that verbal consent at the time of outcome assessment is
the most appropriate design to test this pragmatic inter-
vention. Thus, there is no formal recruitment process;
as mentioned above, all eligible patients within the
registry at the HIU are allocated to intervention or con-
trol one-week post-STEMI. To gain REB approval, we
agreed to provide a note to the family physician of all
included patients describing the patient-reported out-
comes (e.g., current medications and adherence) at the
end of the trial.
Data management
All patient data will be collected directly into a
password-protected database and will not be removed
from the server at the HIU research office. Necessary in-
formation for contacting the participants (e.g., name,
phone number) will be kept in a separate, password-
protected file from the study data, which will have no
patient identifiers. The outcome data (without any iden-
tifiers) will be transferred from the database into a statis-
tical package for analysis.
Analysis
Descriptive statistics will be calculated for all variables of
interest: continuous variables with a normal distribution
will be summarized using means and standard deviations
(medians and inter-quartile ranges in the case of skewed
distributions), whereas categorical variables will be sum-
marized using frequencies and proportions.
We hypothesize that the intervention will result in a
greater proportion of patients who report taking each
cardiovascular medication class of interest at 12 months
post-angiography. The absolute difference in proportionswill be calculated for all primary and secondary dichot-
omous outcomes, together with 95% confidence intervals
adjusting for clustering by family physician [48]. The
statistical significance of differences between arms will
be evaluated using chi-squared tests, adjusted for clus-
tering by family physician.
Exploratory multivariable analyses will be carried out
using generalized estimating equations (GEE) to identify
potential baseline predictors of adherence. Potential ef-
fect modification by treatment—medical management
versus coronary artery bypass graft (CABG) versus
angioplasty—and attendance at cardiac rehabilitation
will be explored by including interactions between these
two variables and group. It is plausible that this analysis
will suggest a need for tailored interventions for these
subgroups. A further exploratory analysis will be con-
ducted focusing on patients who reported taking all five
cardiac medication classes and had perfect MMAS
scores at three months using a multivariable model to
examine covariates predicting late-onset discontinuation.
In addition, a planned sensitivity analysis will exclude
those patients who did not have a family physician, as
we would expect such patients to be more likely to dis-
continue their cardiac medications.
Analyses will be performed on an intention-to-treat
basis. No interim analyses are planned. All analyses will
be carried out using the SAS Version 9.2 statistical pro-
gram (SAS Institute, Cary, NC, USA).
Sample size
The sample size for this design is based on the following
assumptions: an assumed absolute increase in the pro-
portion of patients taking all four cardiovascular medica-
tion classes of 11% at twelve months post-STEMI; an
estimated control group proportion of 50%, and a vari-
ance inflation factor of 1.02 (derived from an intra-
cluster correlation coefficient of 0.019 calculated from
data in the SMART-AMI registry and assuming an aver-
age cluster size of 1.2 based on pilot data). To achieve
80% power to detect a significant main effect of the
intervention using a Chi-squared test at the 5% level of
significance, 652 patients would be required. We will
randomize 815 patients to account for an estimated par-
ticipation rate of 80% at the 12-month follow-up. This
dropout rate is conservative based on similar studies at
the HIU where the participation rate has been greater
than 90% over even longer time periods [40].
The expected effect size is slightly higher than the ef-
fect seen in the previous Canadian trial to account for
the fact that the intervention is multifaceted (directed at
both physician and patient) and occurring later post-
STEMI (reducing the expected control group rate and
therefore the possibility of a ceiling effect). Based on this
sample size calculation, and the rate of STEMI patients
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proximately 15 months to complete the recruitment for
this study.
We will use a kappa statistic to assess agreement be-
tween the self-report of the primary outcome and the
corresponding objective data from the Ontario Drug
Benefit database. Based on an anticipated overall propor-
tion of 56% at 12 months (average of intervention and
control arm) and an anticipated kappa of 0.88, we would
consider acceptable agreement if the lower limit of the
95% confidence interval around kappa does not drop
below 0.80. Therefore we will evaluate validity of the pri-
mary outcome in a random selection of 138 patients
aged 65 or greater.
Process evaluation—optimizing the intervention
A random sample of participating patients will be asked
a series of additional, structured questions at the time of
outcome assessment 90 days post-STEMI. Specifically, a
20% random selection of patients who received the
intervention will be sampled, equating to approximately
80 patients. In addition, all family physicians in the
intervention group will be mailed a one-page question-
naire along with the second iteration of the provider let-
ter (month five post-STEMI). A response rate of only
15% will allow us to get feedback from about 50 family
physicians. The questionnaires to both patient and pro-
vider assess acceptability of the intervention and the rea-
sons for any (lack of) action taken (See Additional file 2:
Appendix D for patient process evaluation questionnaire
and Additional file 2: Appendix E for provider process
evaluation questionnaire). The answers to these ques-
tionnaires will be summarized descriptively and used to
inform future iterations of the intervention.
We also plan to conduct focus groups with both
patients and providers to better understand both why
the intervention did (or did not) work and how it might
be optimized. Participants for these focus groups will be
purposively recruited based on the responses to the
questionnaires. We plan to conduct one or two focus
groups of six to eight patients and one focus group of
four to six physicians, each group lasting about one hour
occurring at the HIU. These focus groups will follow a
semi-structured guide that will be informed by the issues
identified in the questionnaires. The overarching goal of
the focus groups will be to compare and contrast various
designs and approaches of sending reminders to de-
crease the risk of inappropriate medication discontinu-
ation. To this end, a variety of reminder designs will be
handed out among the focus group participants to en-
courage discussion (similar to how marketing firms trad-
itionally have used focus groups). Physician participants
will be provided with $75 (and refreshments). Patient
participants will be offered a $25 gift certificate (andrefreshments) as remuneration for attending the focus
group. The sessions will be recorded and transcribed
verbatim.
Discussion
Discontinuation of cardiac medications post-STEMI
occurs due to patient, provider, and system-level factors
and has important consequences for the patient. This
two-arm, pragmatic, cluster-randomized controlled trial
will test whether mailed reminder letters sent from the
interventional cardiologist to the patient and their family
physician can successfully increase adherence. Even if
the trial does not show a significant effect on medication
discontinuation, the embedded process evaluation will
provide helpful information for planning future inter-
ventions aiming to address this important issue.
Limitations
Although our overall goal is to improve adherence to
medications, it is important to note that our primary out-
come evaluates discontinuation (or ‘persistence’). This
represents the most extreme form of non-adherence. The
allocation is clustered at the level of the family physician
to limit contamination, but it was deemed not feasible to
do the same with pharmacists. Although the tear-away
page in the patient letter for pharmacists could theoretic-
ally bias toward a null finding if pharmacists transfer their
learning from one patient to another, we considered this
risk to be small in comparison to the potential benefit of
facilitating interactions with these key primary care
providers.
It is important to note that this trial will not be able to
discern the relative importance of intervention at patient
versus family physician level. A larger sample size would
be preferable to provide an opportunity to test multiple
ways of designing and delivering this type of interven-
tion within a single trial. In the case of a positive effect,
the pragmatic approach utilized will not allow for infer-
ences regarding the ‘most important’ active ingredients
in the intervention. We intend to explore these issues
through the process evaluation. The questionnaires
developed for the process evaluation are not independ-
ently validated for assessing acceptability and usability of
the reminder intervention. However, they will be evalu-
ated qualitatively to inform iterative improvements to
the program after the trial is completed, and will allow
us to identify interested participants for focus groups.
Although the research coordinator conducting the out-
come assessment will be blinded to allocation, it is pos-
sible that some patients will discuss receiving the
intervention with the coordinator. Another important
caveat is that we will be using patient self-report for main
outcome measurements—an approach which has previ-
ously been used in a similar trial [38]. We are planning to
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comparing patient reported medication use (including the
MMAS) with data recorded in administrative databases
for a subsample of participants above age 65 (for whom
data are accessible using the Ontario Drug Database).
Through these administrative databases, we can also pur-
sue proxy measures for adherence (rather than strictly
discontinuation) by assessing the medication possession
ratio.Implications
Given the proven effectiveness of secondary prevention
medications for reducing morbidity and mortality and
the high risk for poor outcomes in the post-STEMI
population, we believe it is appropriate to power this
trial to show relatively small increases in adherence. Al-
though we would hesitate to extrapolate the findings of
this study without further research, we believe it is im-
portant for quality improvement trials measuring
process outcomes such as adherence to consider the po-
tential for patient-relevant outcomes. To illustrate, con-
sider the systematic review of RCTs of statin-therapy,
which found a number needed to treat (NNT) of 86 to
reduce mortality in patients with CAD [49]. We estimate
that the NNT for avoiding statin discontinuation with
the reminder interventions tested in this trial is approxi-
mately 10. If this were the case, then the NNT for the
reminder interventions to prevent a single mortality
would be 860. In fact, the number might be lower than
this since the intervention may also increase utilization
of the other cardiac medications known to reduce mor-
tality. Given the low-cost, low-risk nature of the inter-
vention in this trial, we believe that NNTs of this size
merit further study for potential population-wide
implementation.Summary
The major strengths of this trial are the pragmatic na-
ture of the intervention the study design. The trial is
well powered and designed specifically to improve health
services for a common problem in patients at high risk
of cardiovascular events. Many quality improvement
trials embark upon highly sophisticated and expensive
interventions; even if successful, sustainability of such
interventions beyond the trial period proves challenging.
Conversely, the DERLA-STEMI intervention would be
easily testable in other healthcare settings and for other
conditions where long-term adherence is suboptimal.
We believe this study will demonstrate the feasibility, ac-
ceptability, and (hopefully) the effectiveness of a sustain-
able and generalizable quality improvement intervention
for STEMI patients.Additional files
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